Key clinical trials of infigratinib

Indication	Phase	Status	Location(s)	Identifier	Sponsor(s)
Cholangiocarcinoma	III	Ongoing	Global	NCT03773302, EudraCT2018-004004-19, PROOF 301	LianBio, QED Therapeutics
Cholangiocarcinoma	II	Ongoing	Global	NCT02150967, EudraCT2013-005085-19	Novartis Pharmaceuticals, QED Therapeutics
Urothelial carcinoma	III	Ongoing	Global	NCT04197986, EudraCT2019-003248-63, PROOF 302	QED Therapeutics
Achondroplasia	II	Ongoing	Global	NCT04265651, EudraCT2019-002954-21, PROPEL 2	QED Therapeutics